Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel by Yi, Hee et al.
Yi et al. BMC Cancer 2010, 10:211
http://www.biomedcentral.com/1471-2407/10/211
Open Access RESEARCH ARTICLE
© 2010 Yi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attri-
bution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Research article Pharmacokinetic properties and antitumor efficacy 
of the 5-fluorouracil loaded PEG-hydrogel
Hee Yi1, Hee-Jung Cho1, Soo-Min Cho1, Dong-Goo Lee1, AM Abd El-Aty1,6, So-Jeong Yoon2, Gun-Won Bae2, 
Kwang Nho2, Bokyung Kim3, Chi-Ho Lee4, Jin-Suk Kim1, Michael G Bartlett5 and Ho-Chul Shin*1
Abstract
Background: We have studied the in vitro and in vivo utility of polyethylene glycol (PEG)-hydrogels for the 
development of an anticancer drug 5-fluorouracil (5-FU) delivery system.
Methods: A 5-FU-loaded PEG-hydrogel was implanted subcutaneously to evaluate the drug retention time and the 
anticancer effect. For the pharmacokinetic study, two groups of male rats were administered either an aqueous 
solution of 5-FU (control group)/or a 5-FU-loaded PEG-hydrogel (treated group) at a dose of 100 mg/kg. For the 
pharmacodynamic study, a human non-small-cell lung adenocarcinoma (NSCLC) cell line, A549 was inoculated to male 
nude mice with a cell density of 3 × 106. Once tumors start growing, the mice were injected with 5-FU/or 5-FU-loaded 
PEG-hydrogel once a week for 4 weeks. The growth of the tumors was monitored by measuring the tumor volume and 
calculating the tumor inhibition rate (IR) over the duration of the study.
Results: In the pharmacokinetic study, the 5-FU-loaded PEG-hydrogel gave a mean residence time (MRT) of 8.0 h and 
the elimination half-life of 0.9 h; these values were 14- and 6-fold, respectively, longer than those for the free solution of 
5-FU (p < 0.05). In the pharmacodynamic study, A549 tumor growth was significantly inhibited in the 5-FU-loaded PEG-
hydrogel group in comparison to the untreated group beginning on Day 14 (p < 0.05-0.01). Moreover, the 5-FU-loaded 
PEG-hydrogel group had a significantly enhanced tumor IR (p < 0.05) compared to the free 5-FU drug treatment group.
Conclusion: We suggest that 5-FU-loaded PEG-hydrogels could provide a useful tool for the development of an 
anticancer drug delivery system.
Background
The drug 5-Fluorouracil (5-FU) is one of the most com-
mon chemotherapeutic agents used against malignant
t u m o r s  [ 1 ] .  H o w ev e r ,  t h i s  d r u g  h a s  s o m e  p h a r m a c o k i -
netic limitations including unfavorable maximum drug
concentrations (Cmax) and short half lives following sys-
temic bolus injection. Earlier reports have demonstrated
that acute increases in plasma 5-FU concentration can
cause severe side effects and the antitumor effects of 5-
FU depend on exposure duration rather than plasma con-
centration levels [2]. Therefore, 5-FU acts more in a time-
dependent manner than in a dose-dependent manner [3-
5]. Therefore, a continuous infusion system for the main-
tenance of intended levels may be beneficial. However,
this approach might be unfavorable due to its high cost
and patient compliance with long-term regimens.
Implantable release devices have been attempted in vivo
to reduce the period of hospitalization and eliminate the
need for indwelling catheters [6]. Recently, we have devel-
oped PEG-hydrogel derivatives as an injectable sustained
release device which can be bolused subcutaneously
without any surgical implantation (US Patent 6858736;
Korean Patent KR 2002-0089772 and 10-2004-0040782).
We have hypothesized that this approach can provide a
diffusional barrier for drug release and thereby deliver
drugs for an extended period of time. In the current
study, we have evaluated the drug release profiles of a 5-
FU-loaded PEG-hydrogel system. To confirm the thera-
peutic efficacy of the designed PEG controlled-release
system, we conducted a pharmacodynamic study using
the A549 tumor xenograft model in nude mice.
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Methods
Chemicals and cell culture materials
The 6-arm PEG-SG (6-arm polyethylene glycol N-
hydroxy succinimidyl glutarate), and 6-arm PEG-AM (6-
arm polyethylene glycol amine) were developed by Sun-
Bio Inc. (An-yang, Republic of Korea). The 5-fluorouracil
(5-FU), NaH2PO4, Na2HPO, methyl alcohol (analytical
grade), and diethyl ether were supplied by Sigma (St.
Louis, MO, USA). Dulbecco's modified Eagle medium
(DMEM), penicillin/streptomycin, and trypsin EDTA
were purchased from GIBCO (Carlsbad, CA, USA).
Aqueous fetal bovine serum (FBS) was obtained from
WelGENE (Daegu, Republic of Korea).
Cell Line and Animals
For the pharmacokinetic study, male Sprague-Dawley rats
were obtained from Orient Bio Inc. (Seongnam, Republic
of Korea). The A549 human lung carcinoma cell line, a
g e n e r o u s  g i f t  f r o m  C h a  B i o m e d i c a l  C e n t e r  ( S e o u l ,
Republic of Korea), was carefully inoculated into the dor-
sal neck of male nude mice (Balb/c Slc-nu/nu), which
were supplied from the Central Lab Animal Inc. (Seoul,
Republic of Korea). All in vivo experiments were carried
out with the approval of the Institutional Animal Care
and Use Committee (IACUC) at Konkuk University and
in harmony with the Guide for Laboratory Animal Care
and Use (IACUC Approval No. KUV7015, 7016)
Preparation of 5-FU-loaded PEG hydrogel and in vitro 
Release of 5-FU-loaded PEG-hydrogel
The 5-FU-loaded PEG-hydrogel was designed as shown
in Fig 1. The 6-arm PEG-AM was dissolved in 10 mM
phosphate buffer (pH 6.0), and 5-FU was added into the
solution at a concentration of 1 mg/ml. The 6-arm PEG-
SG was also dissolved in 10 mM phosphate buffer (pH
6.0). The 6-arm PEG-AM and 6-arm PEG-SG solutions
were prepared at various concentrations (i.e., 7, 10, and
15% w/v). Approximately, 0.5 ml of 6-arm PEG-AM solu-
tion containing 5-FU was placed in a 6-well plate, and an
e q u a l  v o l u m e  o f  6 - a r m  P E G - S G  s o l u t i o n  ( 0 . 5  m l )  w a s
added and mixed. The plate was shaken vigorously until
the solutions hardened, forming the hydrogel. After hard-
ening, the hydrogel was washed gently with 1 ml of 10
mM phosphate buffer (pH 7.2) to remove the any residual
5-FU left on the hydrogel surface. The in vitro release
study was carried out over 8 days. To quantify 5-FU
released from the hydrogel, 2.5 ml of 10 mM phosphate
buffer (pH 7.2) was added into each well and replaced
every day. The plate was sealed and placed at room tem-
perature. The quantity of 5-FU released from the hydro-
gel was measured by monitoring the absorbance at 265
nm. Since the released NHS or other PEG compounds
gave additional signals at this wavelength, we carried out
a n  a d d i t i o n a l  e x p e r i m e n t  t o  a s s e s s  b a c k g r o u n d  v a l u e s
without 5-FU. We calculated the net concentration of 5-
FU by subtracting the background signals resulting from
other compounds from the total signal.
Fig. 1 shows the cross-linking reaction of 6-arm PEG-
amine (PEG-AM) and 6-arm PEG-succinimidyl glutarate
(PEG-SG). When the PEG-SG is mixed with PEG-AM,
PEG-SG separates the N-hydroxy succinimides (NHS)
from its arms. Additionally, the terminals of PEG-SG (-
CO2) are cross-linked with the amine (-NH2) groups of
PEG-AM. This cross-linking between PEG-AM and
PEG-SG changes the two PEG solutions into a gelatinous
form (US Patent 6858736).
Pharmacokinetics
Rats were divided into two groups: a free 5-FU treatment
group and a 5-FU-loaded PEG-hydrogel group. An aque-
ous solution of free 5-FU and a 5-FU-loaded PEG-hydro-
g e l  w e r e  a d m i n i s t e r e d  s u b c u t a n e o u s l y  t o  t h e  r a t s  a t  a
dose of 100 mg/kg. To formulate the 5-FU-loaded PEG-
hydrogel, PEG-SG and PEG-AM containing 5-FU were
dissolved in sodium phosphate buffer (pH 8.0) and mixed
together in equal volumes. The free 5-FU drug solution
was injected into rats using a normal syringe, and the 5-
FU-loaded PEG-hydrogel was injected using a mixing
syringe device (Doowon Meditec Corp., Youngin-city,
Republic of Korea). The aqueous solution of PEG-hydro-
gel (PEG-SG and PEG-AM) immediately changed into a
gel after passing through the injection needle. Blood sam-
ples were collected at minutes (0, 5 and 30) and hours (1,
2, 3, 4, 12, and 24) after drug administration. Sampling
continued until the PEG-hydrogel could not be palpated
under the skin. Blood samples were centrifuged at 8000
rpm for 5 minutes (HANIL Science Industrial Co.,
Inchon, Republic of Korea), and harvested serum (150-
200 μl) was subjected to HPLC analysis [7]. Samples were
extracted using ethyl acetate (6~8 ml) and then evapo-
rated to dryness under N2 gas in a water bath adjusted at
60°C. A 1.5 mM sodium phosphate buffer (pH 5.8) was
added to reconstitute the residue. Approximately 200-300
μl of the reconstituted solutions were filtered and
injected for HPLC (Agilent 1100, Santa Clara, CA, USA).
Separation was accomplished via isocratic elution of the
mobile phase, which contained methanol and 1.5 mM
sodium phosphate buffer (99:1, v/v, pH 5.8), with a flow
rate of 1 ml/min. A C18(Capcell Pak UG120, 5 μm, 4.6 μm
I.D. × 250 μm, Shiseido, Tokyo, Japan) was used as an
analytical column. The analysis was carried out at a col-
umn temperature of 40°C. The wavelengths of the FLD
(fluorescence detector) were 260 nm and 350 nm for exci-
tation and emission, respectively.
Pharmacokinetic parameters were estimated for each
rat by using the program "WinNonlin" to fit the serum
concentration versus time data to the following equation:
Cp = (Ka*F*D)/{Vd*(ka-kel)}*(exp-kel*t - exp-ka*t), where Cp is
the serum concentration and ka and kel are the absorptionYi et al. BMC Cancer 2010, 10:211
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and the elimination rate constants, respectively. The F, D,
and Vd represent the bioavailability, dose, and volume of
distribution, respectively. The lag time was not consid-
ered, and the absorption and elimination rates were
applied using first-order kinetics. The area under the
concentration vursus time curve (AUC0-8 day) was calcu-
lated using the trapezoidal rule from time t = 0 to the last
measured concentration on Day 8. Serum drug concen-
trations and the estimated pharmacokinetic parameters
were reported as means ± SD.
Antitumor Activity of 5-FU-loaded PEG-hydrogels in 
Tumor-bearing Nude Mice
A total of 3 × 106 of cells from the A549 line, a human
non-small-cell lung adenocarcinoma cell line, were inoc-
ulated into the dorsal neck of 4-week-old male nude mice
(Balb/c Slc-nu/nu) as described in earlier reports [7,8].
The tumor mass was monitored every week. When the
tumors grew to 100-400 mm3, the mice were randomized
into three groups: an untreated control group, a free 5-FU
drug control group, and a 5-FU-loaded PEG-hydrogel
group. The free 5-FU drug and 5-FU-loaded PEG-hydro-
gel were prepared as described above was subcutaneously
injecting around the tumor mass once per week for 4
weeks at a dose of 85 mg/kg. Body weight, tumor volume,
and clinical assessment of the mice were monitored every
week until the end of the study. There was no significant
difference in body weight changes among the groups.
When tumors were palpable and visible, the tumor vol-
ume (TV) was measured with a Vernier caliper and cal-
culated using the following formula:
TV(mm ) 1/2 Length Width
32 =× ×
Figure 1 The chemical structures of the 6-arm PEG- AM and 6-arm PEG- SG. PEG-hydrogel network made by 6-arm PEG-AM and 6-arm PEG-SG. 
After displacement of the NHS (N-hydroxy succinimide) from 6-arm PEG-SG, amine residues on 6-arm PEG-AM are cross-linked with 6-arm PEG-SG.Yi et al. BMC Cancer 2010, 10:211
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The antitumor effect was estimated by calculating the
relative tumor volume and the relative tumor inhibition
rate (IR, %). The relative tumor volume (RTV) represents
the tumor volume when the drugs are given to the mice.
where V0 is the tumor volume when the drugs are given
to the mice and Vt is the tumor volume at each measure-
ment.
The TRTV represents the RTV of treated groups, and the
CRTV represents the RTV of the untreated control group.
Histopathological Examination
Sections of A549 taken from subcutaneously trans-
planted tumor masses were fixed with formalin and
embedded in paraffin. Five micrometer tissue sections
were prepared and stained with H & E.
Statistical Analysis
Multiple comparison tests for different treatment groups
were conducted. An ANOVA multiple comparison test
(Dunnett's test) was performed to determine which pairs
of groups differed significantly. An unpaired Student's t-
test was also used to compare the 5-FU-loaded PEG-
hydrogel group versus  the 5-FU-treated control group.
The level of significance was taken as p < 0.05 or 0.01.
Values represent means ± SD. Statistical analyses were
performed with Statistical Analysis Systems software
(SAS/STAT Version 8.1, Cary, NC, USA).
Results
In vitro Release of 5-FU from PEG-hydrogel
The optimal cross-linking reaction was obtained using 1
mM phosphate buffer (pH of 8.0). Fig. 2 presents the
cumulative releases of 5-FU from the 5-FU-loaded PEG-
hydrogel at 7, 10, and 15% PEG concentrations. The 15%
PEG-hydrogel released 5-FU much more slowly than did
the 7% and 10% PEG-hydrogels. Most of the 5-FU in the
7% and 10% of PEG-hydrogels was released within 2 days,
whereas the 15% PEG-hydrogel released 5-FU over a
period of 5 days.
Pharmacokinetics of the Free 5-FU Drug and 5-FU-
loadedPEG-hydrogel
Fig. 3 shows the average serum concentration versus time
curves of 5-FU following subcutaneous administration of
both the free 5-FU drug and 5-FU-loaded PEG-hydrogel
to rats at 100 mg/kg. The 5-FU-loaded PEG-hydrogel
released 5-FU into the serum over a period of one week,
whereas the 5-FU from the free drug injection rapidly
disappeared from the serum within several hours after
injection. The serum concentration profiles for the free 5-
FU and 5-FU-loaded PEG-hydrogel were well described
by a one-compartment open pharmacokinetic model. As
shown in Table 1, between the two groups there were
marked differences in some parameters including the
maximum serum concentrations (Cmax), the elimination
half-lives (t1/2) and the area under the curves (AUC). The
Cmax and t1/2 in the free 5-FU treated group were about 68
μg/ml and 0.15 h, respectively, while those parameters in
5-FU-loaded PEG-hydrogel group were 8 μg/ml and 0.9
h, respectively. In the free 5-FU treated group, the AUC
and the area under the moment curve (AUMC) were
roughly 60 μg h/ml and 33 μg h2/ml, respectively. In the
5-FU-loaded PEG-hydrogel group, the AUC and AUMC
were 14 μg hr/ml and 112 μg h2/ml, respectively.
Tumorigenicity of the A549 Xenograft and Histopathology
A total of 3 × 106 A549 cells were inoculated into nude
mice. The subcutaneous inoculation of tumor cells
resulted in tumor generation at the injection site. Solid
tumors were locally measurable by 1 month after inocula-
tion. As shown in Fig. 4, the relative tumor volume (RTV)
of the untreated control group markedly increased in a
time-dependent manner. However, the RTVs were signifi-
cantly suppressed compared to the untreated group by 5-
FU-loaded PEG-hydrogel treatment starting on Day 14.
However, the free 5-FU drug also showed significant inhi-
bition of tumor volume increases on Day 28. The histo-
pathological examination revealed typical
adenocarcinoma patterns, including the mixed acinar and
tubular form characterized by acini and tubules com-
posed of cuboidal and columnar cells. Poorly differenti-
ated tumor cells are shown among the cells. Some cancer
cells infiltrated into the muscular layer.
Comparative Antitumor Effects of the Free 5-FU and 5-FU 
loaded PEG-hydrogel
Compared to the free 5-FU-treated group, A549 tumor
growth was significantly inhibited in the 5-FU-loaded
PEG-hydrogel group on Day 28 (p < 0.05). The 5-FU-
loaded PEG-hydrogel produced an inhibition rate of 64%,
and the free 5-FU drug produced an inhibition rate of
38%. The PEG-hydrogel itself showed no cytotoxicity for
A549 cells and had no inhibitory effect on tumor growth
in the mouse xenograft (data not shown).
Discussion
Because the use of 5-FU is limited by its short half-life
and rapid elimination, short duration 5-FU bolus admin-
istration has a relatively low response rate [9]. For these
reasons, suitable methods for the administration of 5-FU
have been investigated for a long time [10-12]. Since con-
tinuous intravenous infusion has the advantage of main-
taining a low concentration of the drug in the blood for
RTV(Relative tumor volume) V /V t0 =
IR(InhibitionRate) (1 T /C ) 100 RTV RTV =− ×Yi et al. BMC Cancer 2010, 10:211
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an extended period of time, continuous 5-FU infusion has
been more effective than bolus administration in clinical
trials [13,14]. In comparison to bolus administration,
continuous infusion also minimizes the severe, life-
threatening toxic effects of 5-FU [15,16]. Accordingly,
continuous infusion is an effective method for both
increasing the length of time for which the drug contacts
tumor cells and reducing toxicity. However, continuous
infusion may cause patient discomfort due to indwelling
catheters and bed restriction, and it may give rise to com-
plications like catheter-related vasculitis and sepsis
[15,17]. Therefore, controlled-release devices (e.g., biode-
gradable polymers) have been previously studied for the
development of anticancer drug delivery [18,19].
An optimal crosslinking reaction of PEG-SG and PEG-
AM was observed in 1 mM phosphate buffer at a pH of
8.0. PEG-hydrogel formation was maximized by using
15% concentrations of PEG-AM and PEG-SG. These con-
ditions of PEG-hydrogel formation were applied in our in
vivo pharmacokinetics and antitumor screening studies.
Furthermore, this PEG-hydrogel system is based on a
very simple injection that does not require a surgical pro-
cedure.
Many other groups have reported that the pharmacoki-
netics of 5-FU in patients vary significantly based on the
dosing regimen [20]. In addition, like other anticancer
chemotherapeutics, 5-FU has a relatively narrow thera-
peutic index [21]. For these reasons, controlling the
serum concentration of the drug is important for drug
efficacy and safety. When injected subcutaneously in our
study, 5-FU disappeared rapidly from systemic circula-
tion. On the other hand, the elimination of 5-FU from the
5-FU-loaded PEG-hydrogel showed significantly delayed
release from systemic circulation. The mean residence
time of 8 hours is approximately 14 times higher than that
of free 5-FU administered to animals. Moreover, the
elimination half-life of the 5-FU-loaded PEG-hydrogel
was 0.9 h; this is 6-fold larger than that of the free 5-FU-
treated control group. Blanco et al. [22] also evaluated the
drug release profile of a subcutaneously implanted poly
(2-hydroxyethylmethacrylate-co-acrylamide) hydrogel
containing 5-FU. In this study, the drug was released
Figure 2 In vitro release of 5-FU from PEG-hydrogel. The error bars represent the range from two experiments.Yi et al. BMC Cancer 2010, 10:211
http://www.biomedcentral.com/1471-2407/10/211
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from the poly hydrogel over a span of 2 days. In our study,
the PEG-hydrogel released 5-FU more than 4 days after
the injection. Although Blanco et al. [22] employed a sur-
gical incision for the implantation of the poly hydrogel,
we implanted the hydrogel by direct injection using a
mixing syringe device in which the SG and AM solutions
were immediately changed into a solid gel by mixing
together.
We report that the controlled release of 5-FU from by
the PEG-hydrogel effectively suppressed tumor growth in
vivo. Compared to the free 5-FU-treated control group,
the 5-FU-loaded PEG-hydrogel group demonstrated a
Figure 3 Serum concentration curves for 5-FU following subcutaneous injection of 100 mg/kg of the free 5-FU drug (open circle) and 5-FU-
loaded PEG-hydrogel (closed circle) to SD rats (n = 3). Right panel shows serum concentration curves through 0 to 8 hour.
Table 1: Pharmacokinetic parameters of 5-FU after the subcutaneous injection of 100 mg/kg of the free 5-FU drug and 5-
FU-loaded PEG-hydrogel into SD rats.
Parameters unit 5-FU
(n = 3, Mean ± SD)
5-FU-loaded PEG-hydrogel
(n = 3, Mean ± SD)
Vd/F L 0.41 ± 0.04 10.60 ± 1.55
t1/2(a) h 0.21 ± 0.06 0.06 ± 0.03
t1/2 h 0.15 ± 0.04 0.87 ± 0.17*
CLtot/F l/h 2.04 ± 0.51 8.46 ± 1.07
Cmax μg/ml 67.81 ± 15.84 7.47 ± 1.63
Tmax h 0.25 ± 0.00 0.33 ± 0.14
AUC0-8 day μg·h/ml 59.71 ± 10.58 14.14 ± 1.20
MRT h 0.55 ± 0.03 8.03 ± 4.41*
Vd/F; apparent volume of distribution, t1/2(a); absorption half life, t1/2; elimination half life, CLtot/F; total body clearance, Cmax; maximum serum 
concentration, Tmax; time to maximum concentration, AUC; area under the curve, MRT; mean residence time (AUMC/AUC). * 5-FU vs. 5-FU-
loaded PEG-hydrogel (p < 0.05).Yi et al. BMC Cancer 2010, 10:211
http://www.biomedcentral.com/1471-2407/10/211
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strong tumor growth inhibition effect. Following injec-
tion once a week, the tumor inhibition rate (IR) of the 5-
FU-loaded PEG-hydrogel animals markedly increased
from 20% (Day 7) to 65% (Day 28). In contrast, the IR of
animals in the free 5-FU-treated control group showed a
smaller increase from 30 to 40%. These pharmacody-
namic data demonstrate that the PEG-hydrogel system is
very effective in maintaining the optimal blood concen-
tration of 5-FU necessary to suppress growth of tumor
cells efficiently. The current finding is in agreement with
the fact that 5-FU is not a dose-dependent but rather a
time-dependent drug [3-5].
The common acute toxic effects of 5-FU include myelo-
suppression, mucositis, and diarrhea [15,23,24]. It is gen-
erally understood that the toxicity of 5-FU is related to
the AUC [20,25,26]. In our pharmacokinetic studies, the
AUC and Cmax of 5-FU were markedly decreased after
treatment with the PEG-hydrogel system. These findings
may suggest that 5-FU treatment with a PEG-hydrogel
may be used to reduce the severe toxic effects of this
drug.
Conclusions
Our results suggest that the injectable PEG-hydrogel sys-
tem offers an efficient approach to cancer therapy using a
direct injection method that circumvents surgical inci-
sion.
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